A survey presented at the EADV 2026 Congress found more nail lifting and color changes in GLP-1 users, but the link weakened after adjustments.
Recap by typeshit. Full story at Women's Health.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
Online sellers pitch peptides for weight loss, anti-aging and muscle gain, and Gavin Coote's full story looks at the risks of products nobody regulates.
The Penn dermatologist told Fall Clinical 2026 that in the TOGETHER-PsO trial, tirzepatide plus ixekizumab cut blood pressure by about 8 to 10 mm Hg.
Investseekers points to Fierce Pharma's refreshed chart showing how the two oral obesity pill launches from Novo Nordisk and Eli Lilly are tracking over time.
Loading…